Japan· JP-3999057F1021
デュークラバシチニブ
A deucravacitinib product containing デュークラバシチニブ, registered in Japan by ブリストル・マイヤーズ スクイブ, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Deucravacitinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AF07 (deucravacitinib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Deucravacitinib · ATC L04AF07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of deucravacitinib costs, country by country.
Normalised to the WHO defined daily dose (6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Deucravacitinib · price per daily dose (6 mg)
USD · FX 28 Sept 2026
- FR France$22.97
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- デュークラバシチニブ
- Manufacturer
- ブリストル・マイヤーズ スクイブ
- Country
- Japan (JP)
- ATC code
- L04AF07
- ATC class
- Deucravacitinib
- Defined daily dose
- 6 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L04AF07
Deucravacitinib, as other registers publish it.
- PolandSotyktuBristol-Myers Squibb Pharma EEIG
- NorwaySotyktuBristol-Myers Squibb Pharma EEIG
- FinlandSOTYKTUBristol-Myers Squibb Pharma EEIG
- CzechiaSOTYKTUBristol-Myers Squibb Pharma EEIG, Dublin
- CzechiaSOTYKTUBristol-Myers Squibb Pharma EEIG, Dublin
- CzechiaSOTYKTUBristol-Myers Squibb Pharma EEIG, Dublin
- United StatesSOTYKTUE.R. Squibb & Sons, L.L.C.
- United StatesSOTYKTUE.R. Squibb & Sons, L.L.C.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d0eb8aba-995d-4f4f-983a-0843d71eac96 GET /v1/drugs/d0eb8aba-995d-4f4f-983a-0843d71eac96?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "６ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3999057F1021",
"category": "内用薬",
"price_yen": 2533.4,
"generic_name": "デュークラバシチニブ",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": null
}See everything about deucravacitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.